Newron Pharma (NRWN.SW) Listed on Swiss Exchange
M-Cap : 99,97 Mio CHF ( 88,26 Mio US$ )
Cash : 62,38 Mio CHF ( 55,07 Mio US$ )
Price : 16 CHF
Shares Out : 6,03 Mio
Pipeline
http://www.newron.com/uploads/pipeline_111November3.pdf
Safinamide Significantly Improved Motor Function in Patients with
Advanced Parkinson's Disease in a Phase III Pivotal Trial
http://www.newron.com/uploads/SAfinamidePIIIresultsNewronENG.... ...
Newron reports positive Phase II safety and tolerability results for
HF0220 in Alzheimer's disease
23/10/2008
http://www.newron.com/uploads/HF0220ResultsOct23FinalE%5B1%5.... ...
Homepage
http://www.newron.com/default.asp
DOW JONES NEWSWIRES
By Julia Mengewein 11.03.2009
ZURICH -(Dow Jones)- The ongoing late-stage trial for Newron
Pharmaceuticals SpA's (NWRN.EB) back-pain drug candidate ralfinamide is
going ahead as planned, Chief Financial Officer Stefan Weber told Dow
Jones in an interview Wednesday.
"The trial is going according to plan," Weber said.
News from this study will be pivotal for outlicensing ralfinamide, which
could be the first treatment for neuropathic lower back pain, analysts
say. Newron plans to release full data of the trial early in 2010, but
may strike a deal before then.
"Then (early in 2010) at the latest, we will outlicense the drug," Weber
said. He added that talks with potential partners are already ongoing,
but declined to elaborate further.
Intermediate data so far has shown that the drug is reducing pain for
patients and increasing their quality of life and sleep.
Analysts see sales potential of up to $1.5 billion for ralfinamide in
its best years, with market entry expected for around 2012.
Newron, based in Milan, Italy, but listed in Switzerland, will need
another late-stage trial of ralfinamide for market approval.
"We want to carry out the second study with a partner," Weber said.
Those companies which specialize in pain should be interested in
ralfinamide, analysts say. Among the companies proficient in this area
are Pfizer Inc. (PFE), GlaxoSmithKline PLC. (GSK) and also AstraZeneca
PLC. (AZN.LN).
$6.5 (05/13/09)
